EUCTR2006-005468-25-NO进行中（未招募）不适用
A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO). - ROCC
Retinaklinikken Aleris0 个研究点开始时间: 2006年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female = 50 years
- •2. Patients who have findings consistent with CRVO
- •3. Patients who have a history of decreased visual acuity = 6 months
- •4. Patients who have a best corrected visual acuity (BCVA) letter score in the study eye of = 73 (4 m distance) or = 6 (1 m distance) using an ETDRS chart
- •5. Patients who have a macular edema verified by OCT
- •6. Patients who have macular edema in the study eye with the following characteristics as determined by fluorescein angiography: o secondary to non-iscemic CRVO defined as non-perfusion < 10 DA OR o secondary to ischemic CRVO defined as non-perfusion > 10 DA
- •7. Willing and able to give written informed consent and who are willing and able to comply with study procedures
- •8. Ability to cooperate with photo and OCT examinations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Neovascularisations in the study eye at baseline
- •2. Previous treatment with or participation in a clinical trial (for either eye) involving anti-angiogenics drugs
- •3. Use of other investigational drugs
- •4. Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.
- •5. History of submacular surgery in the study eye, glaucoma filtration, corneal transplantation surgery
- •6. Previous or current intravitreal or sub-Tenon drug delivery in the study eye
- •7. Laserphotocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline
- •8. Extracapsular extraction of cataract with phacoemulcification within three months preceding Baseline, or a history of post-complications within the last 12 months preceding Baseline in the study eye (uveitis, cyclitis etc)
- •9. History of uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment with anti-glaucoma medication)
- •10. Previous violation of the posterior capsule in the study eye unless it occurred as a result of YAG laser posterior capsulotomy in assosiation with prior, posterior chamber lens implantation
- •11. Afakia with absence of the posterior capsule in the study eye
- •12. Active intraocular inflammation in the study eye
- •13. Any active infection involving the ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as ideopathic or autoimmune-associated uveitis in either eye
- •14. Vitreous hemorrhage or history og rhegmatogenous retinal detachment or macular hole in the study eye
- •15. Any current intraocular condition in the study eye (cataract or diabetic retinopathia) that in the opinion of the investigator, could either require medical or surgical intervention during the study period for the next 6 months
- •16. Ocular condition that requires chronic concomitant therapy with systemic or topical ocular corticosteroids.
- •17. Current treatment for active systemic infection.
- •18. Current use or likely need for systemic medications known to be toxic to the lens, retina or optic nerve.
- •19. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or might affect interpretation of the results of the study or render the subject at high risk for treatment complications 20. History of hypersensitivity or allergy to fluorescein
- •21. Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed
- •22. Pregnant or nursing (lactating) women
- •23. Pre-menopausal women of child-bearing potential not using adequate contraception.
- •24. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrance or metastases.
研究者
相似试验
尚未招募
4 期
A study to compare the wound dressings in post cancer surgery woundCTRI/2023/05/052574Dr Amritha Prabha
已完成
不适用
A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects with Primary Open Angle Glaucomaintraocular pressurelowering the pressure in the eye10018307NL-OMON46024InnFocus, Inc.35
已完成
不适用
A randomized trial to compare efficacy and safety of cyclosporin-prednisone versus mycophenolate mofetil-prednisone, 3 months after renal transplantation.Renal transplantationRenal and Urogenital - Kidney diseaseACTRN12610000070033Protocole Hospitalier de Recherche Clinique (PHRC)108
进行中（未招募）
不适用
A randomised trial comparing efficacy and safety after intensification with either insulin aspart once daily as add-on or changing to basal bolus treatment with insulin degludec and insulin aspart in subjects with type 2 diabetes previously treated with insulin degludec/insulin aspart twice dailyMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2012-003152-37-DEovo Nordisk A/S97
进行中（未招募）
1 期
A randomized trial comparing efficacy and safety of etanercept and methotrexate in giant cell arteritis (EFFECTA)Giant cell arteritisCTIS2023-506623-29-01Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy212